Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genetic panel aims to spot heart risk before cancer therapy begins

NCT ID NCT07663357

Diagnosis Sponsor: Beneficência Portuguesa de São Paulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a genetic and epigenetic panel can predict heart damage caused by chemotherapy or immunotherapy in breast cancer patients. Researchers will analyze blood samples from 1,000 participants before and during treatment to see if certain genetic markers signal early risk. The goal is to catch potential heart problems sooner, allowing doctors to adjust treatment and protect patients' hearts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pharmacogenomic panel
What this could lead to
If successful, this could enable doctors to identify patients at high risk for heart damage before starting cancer treatment, allowing for safer, personalized therapy.
What could go wrong
This is an observational study, not a treatment trial. The genetic panel may not accurately predict cardiotoxicity in all patients, and results may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A prospective cohort of adult breast cancer patients receiving cardiotoxic cancer therapies, followed for cardiovascular assessment and multi-omics profiling to identify predictors of treatment-related cardiotoxicity.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and/or HER2-targeted therapies (anti-HER2 therapies). Exclusion Criteria: * Patients with a left ventricular ejection fraction (LVEF) \< 50%; * Patients who have undergone chemotherapy and/or radiotherapy within the previous year; * Patients with chronic kidney disease and a glomerular filtration rate (GFR) \< 30 mL/min/1.73 m²; * Patients with uncontrolled hypertension; * Patients with complex congenital heart disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer Cardiotoxicity neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiotoxicity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complexo Hospitar HUOC/PROCAPE

    NOT_YET_RECRUITING

    Recife, Pernambuco, 50100-130, Brazil

  • FAMERP - Faculdade de Medicina de São José do Rio Preto

    NOT_YET_RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Hospital BP - A Beneficência Portuguesa de São Paulo

    RECRUITING

    São Paulo, São Paulo, 01323-900, Brazil

  • Hospital Beneficente UNIMAR

    NOT_YET_RECRUITING

    Marília, São Paulo, 17525-160, Brazil

  • Instituto do Câncer do Ceará

    NOT_YET_RECRUITING

    Fortaleza, Ceará, 60430-230, Brazil

  • Universidade Federal de Santa Catarina

    NOT_YET_RECRUITING

    Florianópolis, Santa Catarina, 88040-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.